NCT07339254 Experiences w/ & Attitudes Towards Immune Chckpt Inhibitors in NSCLC Patients Single Center Survey Based Study
| NCT ID | NCT07339254 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Southern California |
| Condition | Lung Non-Small Cell Carcinoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 40 participants |
| Start Date | 2026-03-12 |
| Primary Completion | 2027-03-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 40 participants in total. It began in 2026-03-12 with a primary completion date of 2027-03-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study evaluates patient satisfaction with receiving intravenous (IV) and/or subcutaneous (SC) immunotherapy and to assess patient preference for IV immunotherapy administration versus SC immunotherapy administration either at the hospital or at home.
Eligibility Criteria
Inclusion Criteria: * \* Age ≥ 18 years. * \* Patients must have histopathologically/cytologically confirmed non-small cell lung cancer, currently receiving Atezolizumab, Cemiplimab, Durvalumab, Nivolumab, Pembrolizumab (i.e. the patient has already received at least one cycle of therapy) * \* Previous chemotherapy/radiotherapy/targeted/immunotherapy is allowed at any prior timepoint. * \* Ability to understand and the willingness to sign a written informed consent or presence of a surrogate decision maker who can give consent. Exclusion Criteria: * \* Patients is unable to consent for themselves * \* Patient has not yet completed the 1st cycle of ICI-based therapy
Contact & Investigator
Robert Hsu
PRINCIPAL INVESTIGATOR
University of Southern California
Frequently Asked Questions
Who can join the NCT07339254 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Lung Non-Small Cell Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07339254 currently recruiting?
Yes, NCT07339254 is actively recruiting participants. Visit ClinicalTrials.gov or contact University of Southern California to inquire about joining.
Where is the NCT07339254 trial being conducted?
This trial is being conducted at Los Angeles, United States, Los Angeles, United States.
Who is sponsoring the NCT07339254 clinical trial?
NCT07339254 is sponsored by University of Southern California. The principal investigator is Robert Hsu at University of Southern California. The trial plans to enroll 40 participants.